WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406223
Description: BE-16627B is a novel metalloproteinase (MP) inhibitor isolated from Streptomyces sp. BE16627B selectively inhibited MPs such as human stromelysin and 92 kD gelatinase. After the cells were cultured with BE16627B for 5 days, BE16627B inhibited MP activity in the primary culture supernatants from synovial cells in a dose-dependent fashion without showing apparent cytotoxicity or affecting the production and secretion of MPs. Its IC50 for active collagenolysis before activation by trypsin was 25 microM.
MedKoo Cat#: 406223
Chemical Formula: C16H29N3O7
Exact Mass: 375.20055
Molecular Weight: 375.42
Elemental Analysis: C, 51.19; H, 7.79; N, 11.19; O, 29.83
BE-16627B, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: BE16627B; BE 16627B; BE-16627B; LN(Nhydroxy2isobutylsuccinamoyl)serylLvaline.
IUPAC/Chemical Name: (2S)-2-((2S)-3-hydroxy-2-(2-(2-(hydroxyamino)-2-oxoethyl)-4-methylpentanamido)propanamido)-3-methylbutanoic acid
SMILES Code: CC(C)[C@H](NC([C@@H](NC(C(CC(NO)=O)CC(C)C)=O)CO)=O)C(O)=O
The following data is based on the product molecular weight 375.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Yoshida D, Watanabe K, Takahashi H, Sugisaki Y, Teramoto A. Apoptotic induction by BE16627B on human malignant glioma cell lines by an anti-matrix metalloproteinase agent. Brain Tumor Pathol. 2003;20(1):13-9. PubMed PMID: 14604227.
2: Sobue T, Hakeda Y, Kobayashi Y, Hayakawa H, Yamashita K, Aoki T, Kumegawa M, Noguchi T, Hayakawa T. Tissue inhibitor of metalloproteinases 1 and 2 directly stimulate the bone-resorbing activity of isolated mature osteoclasts. J Bone Miner Res. 2001 Dec;16(12):2205-14. PubMed PMID: 11760833.
3: Watanabe K, Yoshida D, Noha M, Teramoto A. Suppression of matrix metalloproteinase-2 and -9 mediated invasiveness by a novel matrix metalloproteinase inhibitor, BE16627B. J Neurooncol. 2001 Mar;52(1):1-9. PubMed PMID: 11451198.
4: Kiyama T, Onda M, Tokunaga A, Efron DT, Barbul A. Effect of matrix metalloproteinase inhibition on colonic anastomotic healing in rats. J Gastrointest Surg. 2001 May-Jun;5(3):303-11. PubMed PMID: 11360054.
5: Shibutani T, Yamashita K, Aoki T, Iwayama Y, Nishikawa T, Hayakawa T. Tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) stimulate osteoclastic bone resorption. J Bone Miner Metab. 1999;17(4):245-51. PubMed PMID: 10575588.
6: Okuyama A, Akiyama T, Nakajima M. [CDK and MMP inhibitors]. Gan To Kagaku Ryoho. 1997 Sep;24(11):1547-62. Review. Japanese. PubMed PMID: 9309154.
7: Tamaki K, Tanzawa K, Kurihara S, Oikawa T, Monma S, Shimada K, Sugimura Y. Synthesis and structure-activity relationships of gelatinase inhibitors derived from matlystatins. Chem Pharm Bull (Tokyo). 1995 Nov;43(11):1883-93. PubMed PMID: 8575029.
8: Okuyama A, Naito K, Morishima H, Suda H, Nishimura S, Tanaka N. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Ann N Y Acad Sci. 1994 Sep 6;732:408-10. PubMed PMID: 7978821.
9: Naito K, Kanbayashi N, Nakajima S, Murai T, Arakawa K, Nishimura S, Okuyama A. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int J Cancer. 1994 Sep 1;58(5):730-5. PubMed PMID: 8077060.
10: Naito K, Nakajima S, Kanbayashi N, Okuyama A, Goto M. Inhibition of metalloproteinase activity of rheumatoid arthritis synovial cells by a new inhibitor [BE16627B; L-N-(N-hydroxy-2-isobutylsuccinamoyl)-seryl-L-valine]. Agents Actions. 1993 Jul;39(3-4):182-6. PubMed PMID: 8304246.